Monthly Archives: September 2004

MHRA message to healthcare professionals. Press Statement. Questions and Answers.

“The Food and Drug Administration (FDA) today acknowledged the voluntary withdrawal from the market of Vioxx (chemical name rofecoxib), a non-steroidal anti-inflammatory drug (NSAID) manufactured by Merck & Co. FDA today also issued a Public Health Advisory to inform patients … Continue reading →

GlaxoSmithKline and Health Canada have issued a warning about an interaction between lamotrigine (Lamictal) and female hormonal contraceptives. A study has shown significant reductions in the blood concentration of lamotrigine in women taken both. There were also reports of break-through … Continue reading →

ADRAC have published their latest bulletin featuring: ADRs to pneumococcal vaccine, risk of suicide with high dose tricyclic antidepressants, terbinafine and blood dyscrasias, cholinesterase inhibitors and cardiac arrhythmias, and quinine and thrombocytopenia. http://www.tga.gov.au/adr/aadrb/aadr0410.pdf

re:Action 30 has just been published with articles on ADRs causing hospital admission, combination antiretrovirals and pancreatitis, photosensitivity reactions and a possible interaction between statins and thiazolidinediones.

“Top officials of the Food and Drug Administration have acknowledged for the first time that antidepressants appeared to lead some children and teenagers to become suicidal. Dr. Robert Temple, director of the food agency’s office of medical policy, said after … Continue reading →

The MHRA has issued advice to consumers and the herbal sector about the poor quality of some traditional chinese medicines (TCMs) on the UK market. Sir Alasdair Breckenridge, Chair of the MHRA said: “We recognise that many consumers value traditional … Continue reading →